Table 4.

Assessment of RAAS Activation Stratified by HIV Status and VAT

	Non-HIV-infected			HIV-infected			Independent Effects P Value by ANOVAc
	VAT < Median (n = 5)	VAT > Median (n = 5)	P Valuea	VAT < Median (n = 10)	VAT > Median (n = 10)	P Valueb	HIV-Positive Status	VAT > Median	HIV-Positive Status * VAT > Median
Metabolic parameters
MAP, mm Hg	87 ± 4	83 ± 3	.38	84 ± 2	85 ± 2	.62
Sodium, mmol/L	138 ± 1	136 ± 2	.30	137 ± 1	137 ± 1	.83
Creatinine, mg/dL	0.90 ± 0.06	0.87 ± 0.10	.79	0.91 ± 0.04	0.93 ± 0.05	.74
Potassium, mmol/L	4.1 ± 0.1	4.0 ± 0.2	.48	4.2 ± 0.1	4.1 ± 0.1	.48
Urine studies
Urine sodium, mmol per 24 h	19.0 ± 3.4	17.4 ± 3.4	.76	28.5 ± 7.9	19.2 ± 4.4	.32
Urine potassium, mmol per 24 h	70.1 ± 9.4	68.3 ± 10.0	.90	63.7 ± 5.2	73.1 ± 7.0	.29
Urine cortisol, μg per 24 h	54.8 [14.6, 72.5]	33.2 [23.8, 39.0]	.68	28.4 [18.7, 41.5]	34.5 [22.6, 45.9]	.57
RAAS parameters
PRA, ng/mL · h	1.30 [1.00, 3.75]	2.30 [0.85, 16.90]	.64	1.45 [0.58, 2.33]	3.50 [2.58, 4.65]	.002	.98	.04	.33
Ang II, pg/mL	28.3 [26.5, 42.6]	31.7 [25.2, 36.4]	.75	29.6 [23.6, 33.9]	36.3 [26.6, 47.1]	.09	.84	.36	.19
Serum aldosterone, ng/dL	8.5 [7.1, 12.8]	9.2 [8.1, 21.5]	.38	11.4 [9.4, 13.8]	27.2 [13.0, 36.9]	.03	.03	.045	.42
Urinary aldosterone excretion, ng per 24 h	33.5 [13.0, 58.5]	34.7 [16.2, 40.4]	.96	19.1 [13.3, 27.9]	32.9 [26.5, 48.6]	.02	.91	.20	.17

Data are reported as mean ± SEM, percentage, or median [interquartile range]. Determinations were performed under conditions of equivalent low-sodium intake for both groups as described in the text.

^aNon-HIV low VAT vs non-HIV high VAT.

^bHIV low VAT vs HIV high VAT.

^cModel to assess interaction between HIV status and VAT among the entire cohort. Crossing of two variables in statistical modeling to determine the interaction between those specific variables.